FERRONE, MARCO
 Distribuzione geografica
Continente #
NA - Nord America 168
EU - Europa 109
AS - Asia 24
AF - Africa 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 305
Nazione #
US - Stati Uniti d'America 165
DE - Germania 39
IT - Italia 37
NL - Olanda 18
CN - Cina 14
SG - Singapore 9
FI - Finlandia 5
IE - Irlanda 5
CA - Canada 3
CI - Costa d'Avorio 3
CH - Svizzera 2
GB - Regno Unito 2
EU - Europa 1
IN - India 1
PT - Portogallo 1
Totale 305
Città #
Chandler 38
Amsterdam 18
Ashburn 14
Millbury 10
Des Moines 7
Napoli 7
Princeton 5
Beijing 4
Boston 4
Changsha 4
Lawrence 4
Nanjing 4
Rome 4
Schoenwalde 4
Singapore 4
Uhlingen-Birkendorf 4
Berlin 3
Los Angeles 3
Ottawa 3
Wilmington 3
Fairfield 2
Freiburg im Breisgau 2
Naples 2
Phoenix 2
Portland 2
Solofra 2
Ann Arbor 1
Bern 1
Boardman 1
Castellabate 1
Coimbra 1
Dublin 1
Jiaxing 1
Kerken 1
Kronberg 1
Milan 1
Nanchang 1
New York 1
Padova 1
Pesaro 1
Plan-les-ouates 1
Sunnyvale 1
Toenisvorst 1
Torino 1
Washington 1
Woodbridge 1
Totale 179
Nome #
Determinants of myocardial mechanics in top-level endurance athletes: three-dimensional speckle tracking evaluation 45
Combined therapy with rotational atherectomy and drug coated balloon for superficial femoral artery in-stent restenosis: safety, efficacy, and two-year results of a single center experience 44
Impact of chronic kidney disease on platelet aggregation in patients with acute coronary syndrome 38
Abluminal biodegradable polymer-based Biolimus A9-eluting stent for the treatment of infrapopliteal arteries in critical limb ischemia: Long-term follow-up 38
Cardiac Side Effects of Chemotherapy: State of Art and Strategies for a Correct Management. 35
Diabetes does not impact the diagnostic performance of contrast-based fractional flow reserve: insights from the CONTRAST study 32
Low-dose quinacrine reduces vascular restenosis without affecting re-endothelialization 27
Complete Revascularization in Acute and Chronic Coronary Syndrome 27
RENASCENT II: First in Human Evaluation of a Novel Sirolimus-Eluting Ultra-High Molecular Weight APTITUDE® Bioresorbable Scaffold: 9-and 24-Months Imaging and Clinical Results 22
First in human evaluation of a novel Sirolimus-eluting ultra-high molecular weight bioresorbable scaffold: 9-, 24-and 36-months imaging and clinical results from the multi-center RENASCENT study 20
Totale 328
Categoria #
all - tutte 1.302
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.302


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202020 6 0 0 0 0 0 0 0 6 2 5 1
2020/202130 1 3 1 8 2 2 6 1 5 0 1 0
2021/202257 1 0 0 0 0 1 1 1 8 4 19 22
2022/202396 9 4 5 4 10 15 0 5 18 18 4 4
2023/202487 1 11 4 18 23 9 0 4 1 7 7 2
Totale 328